DENVER – The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment. Potential solutions to reducing or eliminating these barriers include routine tissue banking at diagnosis, easing use of available diagnostic samples, development of less invasive tests, faster turnaround time at central laboratories or allowing for local testing and more resources for timely tissue collection.
DENVER – The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another round of hope with the FDA’s rapid progression of lung cancer drug approvals – this time for alectinib (Alecensa, Roche/Genenetech) for patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) if their disease deteriorated after treatment with another therapy called crizotinib (Xalkori, Pfizer). Patients who could not tolerate treatment with crizotinib also qualify for use of alectinib.
DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased to hear of another approval by the U.S. Food and Drug Administration (FDA) that helps in the fight against lung cancer – the fourth in two months. The FDA approved necitumumab (PortrazzaTM) in combination with standard chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for their advanced disease.
FDA Approves New Therapy Option for Lung Cancer Patients Who Develop Resistance to Early Generation EGFR Inhibitors
DENVER – The International Association for the Study of Lung Cancer (IASLC) commends the U.S. Food and Drug Administration’s (FDA) decision to grant accelerated approval for osimertinib (TagrissoTM), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
DENVER – During November’s Lung Cancer Awareness Month, the International Association for the Study of Lung Cancer (IASLC) wants to highlight the importance of immunotherapy, a form of personalized medicine and a groundbreaking tool in the fight against lung cancer.
Sorafenib Modestly Increases Progression-Free Survival But Not Overall Survival in NSCLC Patients Who Failed Previous Therapies
DENVER – Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.